Glenmark Pharmaceuticals Ltd reply to clarification sought by the exchange
The Exchange had sought clarification from Glenmark Pharmaceuticals Ltd with respect to news article appearing on economictimes.indiatimes.com - July 13, 2018 "CCI penalises Glenmark Pharma, other entities for unfair business practices"Glenmark Pharmaceuticals Ltd response is enclosed. Announcement under Regulation 30 (LODR)-Press Release / Media Release
Sub: Glenmark Pharmaceuticals receives ANDA approval for Colesevelam Hydrochloride for Oral Suspension, 1.875 grams/Packet and 3.75 grams/Packet. Announcement under Regulation 30 (LODR)-Updates on Acquisition
Sub: Update on intimation made pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015- Acquisition of 100% equity shareholding in Zorg Laboratories Private Limited (Zorg) by Glenmark Pharmaceuticals Limited (the Company) Reference is made to the intimation made to the Stock exchanges on May 29, 2018 by the Company in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure... Clarification sought fromGlenmark Pharmaceuticals Ltd
The Exchange has sought clarification from Glenmark Pharmaceuticals Ltd with respect to news article appearing on economictimes.indiatimes.com - July 13, 2018 titled "CCI penalises Glenmark Pharma, other entities for unfair business practices". The reply is awaited. Announcement under Regulation 30 (LODR)-Credit Rating
Sub:- Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015 - Credit Rating by Fitch Ratings Glenmark would like to inform you that Fitch Ratings, as part of their annual review cycle, has reaffirmed the Company's credit rating at 'BB', outlook 'stable'. The agency also affirmed the rating on Company's USD200 million 4.50% senior unsecured notes issued in 2016 at ''BB''.... Glenmark launches Akynzeo in India under licensing pact with Helsinn
Glenmark Pharmaceuticals today launched Akynzeo, a drug used for the prevention of chemotherapy-induced nausea and vomiting, in India and Nepal unde
Glenmark inks pact with Seqirus to commercialise Ryaltris in Australia, New Zealand
Ryaltris is indicated for treatment of symptoms associated with seasonal allergic rhinitis (SAR) in patients over 12 years of age Statement Of Investor Complaints For The Quarter Ended June 2018
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 013130 Name of the Signatory :- Harish KuberDesignation :- Company Secretary and Compliance Officer Announcement under Regulation 30 (LODR)-Press Release / Media Release
Sub: Glenmark Pharmaceuticals Announces Exclusive Licensing Agreement with Seqirus for its Investigational Seasonal Allergic Rhinitis Nasal Spray - Ryaltris - for Australia and New Zealand Markets Glenmark's US facility to go onstream with nod for anti-malaria drug
Market size of drug is $40 mn. Having a manufacturing footprint in the US is part of company's game plan to mitigate regulatory risk